Abstract
Current knowledge of the haematological and onco-haematological complications of type 1 Gaucher disease has been reviewed with the aim of identifying best clinical practice for treatment and disease management. It was concluded that: (i) Awareness of typical patterns of cytopenia can help clinicians distinguish haematological co-morbidities. (ii) Red blood cell studies and complete iron metabolism evaluation at baseline are recommended. (iii) Haemoglobin levels defining anaemia should be raised and used in Gaucher disease treatment and monitoring. (iv) Surgeons should be aware of potential bleeding complications during surgery in Gaucher patients. The higher incidence of multiple myeloma in Gaucher disease suggests that Gaucher patients should have their immunoglobulin profile determined at diagnosis and monitored every 2 years (patients 50 years). If monoclonal gammopathy of undetermined significance (MGUS) is found, general MGUS guidelines should be followed. Future studies should focus on the utility of early treatment to prevent immunoglobulin abnormalities and multiple myeloma.
| Original language | English |
|---|---|
| Pages (from-to) | 676-686 |
| Number of pages | 11 |
| Journal | British Journal of Haematology |
| Volume | 138 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Sep 2007 |
Fingerprint
Keywords
- Clinical haematology
- Gaucher disease
- Haematological malignancy
ASJC Scopus subject areas
- Hematology
Cite this
Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. / Hughes, Derralynn; Cappellini, Maria Domenica; Berger, Marc; Van Droogenbroeck, Jan; De Fost, Maaike; Janic, Dragana; Marinakis, Theodore; Rosenbaum, Hanna; Villarubia, Jesús; Zhukovskaya, Elena; Hollak, Carla.
In: British Journal of Haematology, Vol. 138, No. 6, 09.2007, p. 676-686.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease
AU - Hughes, Derralynn
AU - Cappellini, Maria Domenica
AU - Berger, Marc
AU - Van Droogenbroeck, Jan
AU - De Fost, Maaike
AU - Janic, Dragana
AU - Marinakis, Theodore
AU - Rosenbaum, Hanna
AU - Villarubia, Jesús
AU - Zhukovskaya, Elena
AU - Hollak, Carla
PY - 2007/9
Y1 - 2007/9
N2 - Current knowledge of the haematological and onco-haematological complications of type 1 Gaucher disease has been reviewed with the aim of identifying best clinical practice for treatment and disease management. It was concluded that: (i) Awareness of typical patterns of cytopenia can help clinicians distinguish haematological co-morbidities. (ii) Red blood cell studies and complete iron metabolism evaluation at baseline are recommended. (iii) Haemoglobin levels defining anaemia should be raised and used in Gaucher disease treatment and monitoring. (iv) Surgeons should be aware of potential bleeding complications during surgery in Gaucher patients. The higher incidence of multiple myeloma in Gaucher disease suggests that Gaucher patients should have their immunoglobulin profile determined at diagnosis and monitored every 2 years (patients 50 years). If monoclonal gammopathy of undetermined significance (MGUS) is found, general MGUS guidelines should be followed. Future studies should focus on the utility of early treatment to prevent immunoglobulin abnormalities and multiple myeloma.
AB - Current knowledge of the haematological and onco-haematological complications of type 1 Gaucher disease has been reviewed with the aim of identifying best clinical practice for treatment and disease management. It was concluded that: (i) Awareness of typical patterns of cytopenia can help clinicians distinguish haematological co-morbidities. (ii) Red blood cell studies and complete iron metabolism evaluation at baseline are recommended. (iii) Haemoglobin levels defining anaemia should be raised and used in Gaucher disease treatment and monitoring. (iv) Surgeons should be aware of potential bleeding complications during surgery in Gaucher patients. The higher incidence of multiple myeloma in Gaucher disease suggests that Gaucher patients should have their immunoglobulin profile determined at diagnosis and monitored every 2 years (patients 50 years). If monoclonal gammopathy of undetermined significance (MGUS) is found, general MGUS guidelines should be followed. Future studies should focus on the utility of early treatment to prevent immunoglobulin abnormalities and multiple myeloma.
KW - Clinical haematology
KW - Gaucher disease
KW - Haematological malignancy
UR - http://www.scopus.com/inward/record.url?scp=34548175657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548175657&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2007.06701.x
DO - 10.1111/j.1365-2141.2007.06701.x
M3 - Article
VL - 138
SP - 676
EP - 686
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 6
ER -